Saturday, July 11, 2026

Patent directory · USPTO A61K / A61P

Patents matching “combination”

418 pharma patents match "combination" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 418
Index total 30,257
Page 5 / 18

Quick answer

This filtered view shows 418 pharmaceutical patents matching "combination" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

418 results for “combination” · 30,257 patents in full index Clear search

  1. US 11510929

    Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids

    The Regents of the University of California · Granted Nov 29, 2022 · Expires Nov 24, 2042

    granted
  2. US 11497781

    Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus CG0070 and an immune checkpoint inhibitor

    CG ONCOLOGY, INC. · Granted Nov 15, 2022 · Expires Nov 10, 2042

    granted
  3. US 11497713

    Combination taxoid nanoemulsion with immunotherapy in cancer

    Northwestern University · Granted Nov 15, 2022 · Expires Nov 10, 2042

    granted
  4. US 11491215

    Antigenic combinations against Francisella bacteria and related nanolipoprotein particles, compositions, methods and systems

    The Regents of the University of New Mexico · Granted Nov 8, 2022 · Expires Nov 3, 2042

    granted
  5. US 11491145

    Combination therapies comprising targeted therapeutics

    Madrigal Pharmaceuticals, Inc. · Granted Nov 8, 2022 · Expires Nov 3, 2042

    granted
  6. US 11478428

    Combinations of beta-lactam compounds and probenecid and uses thereof

    Iterum Therapeutics International Limited · Granted Oct 25, 2022 · Expires Oct 20, 2042

    granted
  7. US 11464774

    Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Oct 11, 2022 · Expires Oct 6, 2042

    granted
  8. US 11464856

    Combination therapy using inhibitors of human growth and differentiation factor 15 (GDF-15) and immune checkpoint blockers

    Julius-Maximilians-Universitat Wurzburg · Granted Oct 11, 2022 · Expires Oct 6, 2042

    granted
  9. US 11464768

    Pimavanserin alone or in combination for use in the treatment of Alzheimer's disease psychosis

    ACADIA Pharmaceuticals Inc. · Granted Oct 11, 2022 · Expires Oct 6, 2042

    granted
  10. US 11458127

    Methods of treating brain tumors using combination therapy

    Agios Pharmaceuticals, Inc. · Granted Oct 4, 2022 · Expires Sep 29, 2042

    granted
  11. US 11452723

    Combination dosage form of a mu opioid receptor antagonist and an opioid agent

    Theravance Biopharma R&D IP, LLC · Granted Sep 27, 2022 · Expires Sep 22, 2042

    granted
  12. US 11440963

    Combination PDL1 and TGF-beta blockade in patients with HPV+ malignancies

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Sep 13, 2022 · Expires Sep 8, 2042

    granted
  13. US 11426379

    Combination of local and systemic therapies for enhanced treatment of dermatologic conditions

    Provectus Pharmatech, Inc. · Granted Aug 30, 2022 · Expires Aug 25, 2042

    granted
  14. US 11421034

    Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic cancer

    Five Prime Therapeutics, Inc. · Granted Aug 23, 2022 · Expires Aug 18, 2042

    granted
  15. US 11414489

    Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor

    HALOZYME, INC. · Granted Aug 16, 2022 · Expires Aug 11, 2042

    granted
  16. US 11400123

    Combination product for prophylaxis and treatment of irritable bowel syndrome

    PrecisionBiotics Group Limited · Granted Aug 2, 2022 · Expires Jul 28, 2042

    granted
  17. US 11397184

    Selection of patients for combination therapy

    Syndax Pharmaceuticals, Inc. · Granted Jul 26, 2022 · Expires Jul 21, 2042

    granted
  18. US 11382897

    Therapeutic combination for treatment of cerebellar ataxia

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Jul 12, 2022 · Expires Jul 7, 2042

    granted
  19. US 11365265

    Anti-C5 antibody combinations and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 21, 2022 · Expires Jun 16, 2042

    granted
  20. US 11357795

    Combination immunotherapies for treatment of cancer

    PrimeVax Immuno-Oncology · Granted Jun 14, 2022 · Expires Jun 9, 2042

    granted
  21. US 11351153

    Antimicrobial compositions containing a synergistic combination of activated creatinine and an imidazole antifungal agent

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Jun 7, 2022 · Expires Jun 2, 2042

    granted
  22. US 11338013

    Combination therapy for C3 inhibition

    Apellis Pharmaceuticals, Inc. · Granted May 24, 2022 · Expires May 19, 2042

    granted
  23. US 11331370

    Combination product for the prevention of sexually transmitted infections

    The United States of America · Granted May 17, 2022 · Expires May 12, 2042

    granted
  24. US 11324822

    Combination of HDAC inhibitor and anti-PD-1 antibody for treatment of cancer

    Syndax Pharmaceuticals, Inc. · Granted May 10, 2022 · Expires May 5, 2042

    granted